Recently, Legding Micros, a Beijing-based company focusing on R&D in the ophthalmology field, announced the completion of a new round of financing. This round was led by the BioWin Hundred Talents Fund of Wuhan Biotechnology Research Institute, with ZYTH Fund (under Zhongxi Fund) participating as a follower.
It is reported that this round of financing will be used for the company's team building, and to advance the research, development, and clinical registration of meibomian gland devices and ophthalmic surgical robots.
Legding Micros, established in 2022, is a developer of ophthalmic surgical robots, focusing on the field of ophthalmic surgical robotics. The company is advancing the finalization and inspection submission of its third-generation ophthalmic surgical robot while initiating the application process for medical device registration certificates for other products in its pipeline, including devices for dry eye syndrome treatment.
Currently, Legding Micros has iterated to the third generation of ophthalmic surgical robot systems, with technical specifications keeping pace with world-class standards. The overall size of the system continues to shrink, while precision and stability meet the requirements for most intraocular minimally invasive surgeries. This is mainly due to the company's accumulated technical advantages in areas such as robotic end-effector sensing and precision manufacturing.
At the same time, Legding Micros has planned three product pipelines: The first pipeline is a meibomian gland massager, used to alleviate symptoms such as dry eyes caused by blocked meibomian glands. The second pipeline is a retinal surgery robot, used for subretinal and retinal vascular puncture injection to treat diseases like macular degeneration and retinal vascular occlusion. The third pipeline is a handheld intelligent surgical instrument, which can actively suppress hand tremors through special structures and algorithms, assisting doctors in performing complex operations such as peeling retinal proliferative membranes.
In the next two to three years, Legding Micros' main task is to obtain the Class III medical device certificate for its ophthalmic surgical robot and is expected to target ophthalmic hospitals as its customer base. Currently, the company is advancing the finalization and inspection process of the product while also initiating applications for medical device registration certificates for other products in its pipeline, including devices for dry eye syndrome treatment.